These findings highlight the potential of targeting TRPA1 in combination with chemotherapy as a therapeutic strategy for breast cancer treatment, particularly in triple-negative breast cancer cases where effective treatment options are limited. This evidence concerns the gene TRPA1 and breast carcinoma.